Absorbed doses in the marrow during 131I therapy

Area of Science:

• Nuclear medicine
• Medical physics
• Endocrinology

Background:

• Radioactive iodine (131I) therapy is a standard treatment for hyperthyroidism.
• Accurate absorbed dose calculations are essential for optimizing therapeutic efficacy and minimizing side effects.
• Previous dose estimates may not reflect the most current data and methodologies.

Purpose of the Study:

• To re-evaluate absorbed doses to red marrow and blood from 131I therapy.
• To compare new dose estimates with previously published data.
• To discuss uncertainties associated with the dose calculations.

Main Methods:

• Utilized recently available data for dose calculations.
• Performed re-evaluation of absorbed doses to red marrow and blood.
• Analyzed uncertainties in the computational methods.

Main Results:

• The mean absorbed dose to red marrow for hyperthyroid patients is estimated at 0.59 rad mCi-1.
• The mean absorbed dose to red marrow for euthyroid states is estimated at 0.36 rad mCi-1.
• Comparison with previous estimates highlights differences in calculated absorbed doses.

Conclusions:

• Updated absorbed dose calculations provide a more refined estimate for red marrow exposure during 131I therapy.
• The findings underscore the importance of using current data for accurate dosimetry in nuclear medicine.
• Further investigation into uncertainties can improve the precision of radiation dose estimations.